InnoCare Pharma Limited (HKG:9969)
Hong Kong · Delayed Price · Currency is HKD 13.11
+0.71 (5.73%)
At close: Mar 27, 2026
InnoCare Pharma Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 2,375 | 1,008 | 736.99 | 625.4 | 1,043 |
Other Revenue | - | 1.8 | 1.55 | - | - |
| 2,375 | 1,009 | 738.54 | 625.4 | 1,043 | |
Revenue Growth (YoY) | 135.27% | 36.68% | 18.09% | -40.04% | 76368.70% |
Cost of Revenue | 191.11 | 138.44 | 128.44 | 143.4 | 65.67 |
Gross Profit | 2,184 | 871.01 | 610.1 | 482.01 | 977.37 |
Selling, General & Admin | 783.47 | 588.49 | 551.01 | 613.27 | 436.89 |
Research & Development | 951.62 | 814.61 | 757.25 | 639.14 | 721.58 |
Other Operating Expenses | -262.18 | 11.13 | -26.76 | 7 | 1.42 |
Operating Expenses | 1,473 | 1,416 | 1,282 | 1,259 | 1,160 |
Operating Income | 710.48 | -544.71 | -671.67 | -777.4 | -182.53 |
Interest Expense | -54.13 | -33.79 | -35.21 | -17.05 | -2.64 |
Interest & Investment Income | - | 178.71 | 197.9 | 145.4 | 135.21 |
Earnings From Equity Investments | -0.2 | - | - | -9.71 | -0.6 |
Currency Exchange Gain (Loss) | - | -43.65 | -87.84 | - | 57.14 |
Other Non Operating Income (Expenses) | -0.41 | -0.38 | 6.57 | -244.93 | 17.59 |
EBT Excluding Unusual Items | 655.74 | -443.83 | -590.24 | -903.68 | 24.16 |
Gain (Loss) on Sale of Investments | - | -30.46 | -53.96 | 6.56 | 6.73 |
Asset Writedown | - | -0.1 | - | - | - |
Other Unusual Items | - | 21.81 | - | 3.4 | -51.01 |
Pretax Income | 655.74 | -452.59 | -644.21 | -893.73 | -20.12 |
Income Tax Expense | 11.56 | 0.26 | 1.43 | - | 46.56 |
Earnings From Continuing Operations | 644.18 | -452.86 | -645.63 | -893.73 | -66.68 |
Minority Interest in Earnings | -1.72 | 12.22 | 14.37 | 7.13 | 2.13 |
Net Income | 642.47 | -440.63 | -631.26 | -886.59 | -64.55 |
Net Income to Common | 642.47 | -440.63 | -631.26 | -886.59 | -64.55 |
Shares Outstanding (Basic) | - | 1,695 | 1,706 | 1,480 | 1,366 |
Shares Outstanding (Diluted) | - | 1,695 | 1,706 | 1,480 | 1,366 |
Shares Change (YoY) | - | -0.67% | 15.31% | 8.29% | 41.21% |
EPS (Basic) | - | -0.26 | -0.37 | -0.60 | -0.05 |
EPS (Diluted) | - | -0.26 | -0.37 | -0.60 | -0.05 |
Free Cash Flow | - | -443.78 | -920.14 | -792.79 | -2.71 |
Free Cash Flow Per Share | - | -0.26 | -0.54 | -0.54 | -0.00 |
Gross Margin | 91.95% | 86.28% | 82.61% | 77.07% | 93.70% |
Operating Margin | 29.92% | -53.96% | -90.95% | -124.30% | -17.50% |
Profit Margin | 27.05% | -43.65% | -85.47% | -141.76% | -6.19% |
Free Cash Flow Margin | - | -43.96% | -124.59% | -126.76% | -0.26% |
EBITDA | 777.5 | -477.69 | -611.8 | -731.46 | -167.2 |
EBITDA Margin | 32.74% | -47.32% | -82.84% | -116.96% | -16.03% |
D&A For EBITDA | 67.02 | 67.02 | 59.87 | 45.94 | 15.33 |
EBIT | 710.48 | -544.71 | -671.67 | -777.4 | -182.53 |
EBIT Margin | 29.92% | -53.96% | -90.95% | -124.30% | -17.50% |
Effective Tax Rate | 1.76% | - | - | - | - |
Revenue as Reported | - | 1,009 | 738.54 | - | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.